362 related articles for article (PubMed ID: 29597249)
21. Diagnostic, prognostic and therapeutic role of CD30 in lymphoma.
Pierce JM; Mehta A
Expert Rev Hematol; 2017 Jan; 10(1):29-37. PubMed ID: 27927047
[TBL] [Abstract][Full Text] [Related]
22. Analysis of gene expression profile of TPM3-ALK positive anaplastic large cell lymphoma reveals overlapping and unique patterns with that of NPM-ALK positive anaplastic large cell lymphoma.
Bohling SD; Jenson SD; Crockett DK; Schumacher JA; Elenitoba-Johnson KS; Lim MS
Leuk Res; 2008 Mar; 32(3):383-93. PubMed ID: 17720243
[TBL] [Abstract][Full Text] [Related]
23. Immunohistochemistry of Hodgkin and non-Hodgkin lymphomas with emphasis on the diagnostic significance of the BNH9 antibody reactivity with anaplastic large cell (CD30 positive) lymphomas.
Carbone A; Gloghini A; Volpe R
Cancer; 1992 Dec; 70(11):2691-8. PubMed ID: 1330287
[TBL] [Abstract][Full Text] [Related]
24. Therapeutic Use of Brentuximab Vedotin in CD30+ Hematologic Malignancies.
Fabbri A; Cencini E; Gozzetti A; Schiattone L; Bocchia M
Anticancer Agents Med Chem; 2017; 17(7):886-895. PubMed ID: 27592544
[TBL] [Abstract][Full Text] [Related]
25. Anaplastic Large Cell Lymphoma.
Medeiros LJ; Elenitoba-Johnson KS
Am J Clin Pathol; 2007 May; 127(5):707-22. PubMed ID: 17511113
[TBL] [Abstract][Full Text] [Related]
26. The histologic, immunohistochemical, and genetic features of classical Hodgkin lymphoma and anaplastic large cell lymphoma with aberrant T-cell/B-cell antigen expression.
Liang K; Wang J; Wang Y; Zhou Z; Ge S; Mei S; Li H; Jing X; Zhang C
Hum Pathol; 2019 Feb; 84():309-320. PubMed ID: 30339972
[TBL] [Abstract][Full Text] [Related]
27. [Analysis of mature T-cell and NK-cell lymphoma with CD30 expression based on latest WHO classification].
Feng Y; Fu J; Yan S; Ling Y; Huang Y; Cai M; Rao H
Zhonghua Bing Li Xue Za Zhi; 2014 Aug; 43(8):508-11. PubMed ID: 25346118
[TBL] [Abstract][Full Text] [Related]
28. The helix-loop-helix protein Id2 is expressed differentially and induced by myc in T-cell lymphomas.
Cotta CV; Leventaki V; Atsaves V; Vidaki A; Schlette E; Jones D; Medeiros LJ; Rassidakis GZ
Cancer; 2008 Feb; 112(3):552-61. PubMed ID: 18085637
[TBL] [Abstract][Full Text] [Related]
29. The expression of CD30 in anaplastic large cell lymphoma is regulated by nucleophosmin-anaplastic lymphoma kinase-mediated JunB level in a cell type-specific manner.
Hsu FY; Johnston PB; Burke KA; Zhao Y
Cancer Res; 2006 Sep; 66(18):9002-8. PubMed ID: 16982741
[TBL] [Abstract][Full Text] [Related]
30. Brefeldin A exerts differential effects on anaplastic lymphoma kinase positive anaplastic large cell lymphoma and classical Hodgkin lymphoma cell lines.
Toda T; Watanabe M; Kawato J; Kadin ME; Higashihara M; Kunisada T; Umezawa K; Horie R
Br J Haematol; 2015 Sep; 170(6):837-46. PubMed ID: 26105086
[TBL] [Abstract][Full Text] [Related]
31. FOXP3-positive T-cell lymphomas in non-HTLV1 carriers include ALK-negative anaplastic large cell lymphoma: expanding the spectrum of T-cell lymphomas with regulatory phenotype.
Ferreira CR; Zhao S; Sahoo MK; Pinsky B; Weber J; Lage LAPC; Pereira J; Zerbini MCN; Natkunam Y
Hum Pathol; 2018 Oct; 80():138-144. PubMed ID: 29898383
[TBL] [Abstract][Full Text] [Related]
32. Systemic and primary cutaneous anaplastic large cell lymphoma: Clinical features, morphological spectrum, and immunohistochemical profile.
Kwatra KS; Paul PAM; Calton N; John JM; Cotelingam JD
South Asian J Cancer; 2017; 6(3):129-131. PubMed ID: 28975123
[TBL] [Abstract][Full Text] [Related]
33. Insight into the molecular function and transcriptional regulation of activator protein 1 (AP-1) components c-Jun/c-Fos ortholog in red lip mullet (Liza haematocheila).
Janson ND; Jehanathan N; Jung S; Priyathilaka TT; Nam BH; Kim MJ; Lee J
Fish Shellfish Immunol; 2019 Oct; 93():597-611. PubMed ID: 31400511
[TBL] [Abstract][Full Text] [Related]
34. PAX-5 Positivity in Anaplastic Lymphoma Kinase-Negative Anaplastic Large Cell Lymphoma: A Case Report and Review of Literature.
Arun I; Roy P; Arora N; Bhave SJ; Nair R; Chandy M
Int J Surg Pathol; 2017 Jun; 25(4):333-338. PubMed ID: 28013563
[TBL] [Abstract][Full Text] [Related]
35. Challenges of driving CD30-directed CAR-T cells to the clinic.
Grover NS; Savoldo B
BMC Cancer; 2019 Mar; 19(1):203. PubMed ID: 30841880
[TBL] [Abstract][Full Text] [Related]
36. mRNA expression patterns indicate CD30 mediated activation of different apoptosis pathways in anaplastic large cell lymphoma but not in Hodgkin's lymphoma.
Staber PB; Noehammer C; Dürkop H; Schauer S; Kenner L; Linkesch W; Hoefler G
Leuk Res; 2006 Mar; 30(3):343-8. PubMed ID: 16198418
[TBL] [Abstract][Full Text] [Related]
37. Abnormal AP-1 protein expression in primary cutaneous B-cell lymphomas.
Mao X; Orchard G
Br J Dermatol; 2008 Jul; 159(1):145-51. PubMed ID: 18460027
[TBL] [Abstract][Full Text] [Related]
38. Aberrantly expressed c-Jun and JunB are a hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NF-kappa B.
Mathas S; Hinz M; Anagnostopoulos I; Krappmann D; Lietz A; Jundt F; Bommert K; Mechta-Grigoriou F; Stein H; Dörken B; Scheidereit C
EMBO J; 2002 Aug; 21(15):4104-13. PubMed ID: 12145210
[TBL] [Abstract][Full Text] [Related]
39. MUM1 expression in cutaneous CD30+ lymphoproliferative disorders: a valuable tool for the distinction between lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma.
Kempf W; Kutzner H; Cozzio A; Sander CA; Pfaltz MC; Müller B; Pfaltz M
Br J Dermatol; 2008 Jun; 158(6):1280-7. PubMed ID: 18410414
[TBL] [Abstract][Full Text] [Related]
40. Cytotoxic protein expression in non-Hodgkin's lymphomas and Hodgkin's disease.
Kanavaros P; Vlychou M; Stefanaki K; Rontogianni D; Gaulard P; Pantelidaki E; Zois M; Darivianaki K; Georgoulias V; Boulland ML; Gorgoulis V; Kittas C
Anticancer Res; 1999; 19(2A):1209-16. PubMed ID: 10368677
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
